Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study

Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study

Abstract Objectives Crizotinib has demonstrated good efficacy in patients with anaplastic lymphoma kinase (ALK)‐positive non‐small cell lung cancer (NSCLC). Continuing crizotinib therapy beyond progressive disease (CBPD) can achieve ongoing survival benefit in real‐world clinical practice. In terms...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Guangjian Yang, Di Ma, Haiyan Xu, Lu Yang, Junling Li, Puyuan Xing, Xuezhi Hao, Yan Wang
Format:	Artykuł
Język:	English
Wydane:	Wiley 2019-10-01
Seria:	Cancer Medicine
Hasła przedmiotowe:	anaplastic lymphoma kinase inhibitor crizotinib crizotinib continuation beyond progressive disease non‐small cell lung cancer treatment duration
Dostęp online:	https://doi.org/10.1002/cam4.2420

Podobne zapisy

Three years sustained complete remission achieved in a primary refractory ALK-positive anaplastic T large cell lymphoma treated with crizotinib
od: Carolina Valeria Mahuad, i wsp.
Wydane: (2016-06-01)

Clinical Efficacy of Crizotinib in Treatment of Patients with Advanced NSCLC
od: Emei GAO, i wsp.
Wydane: (2016-03-01)

The Use of Crizotinib in Sclerosing Epithelioid Fibrosarcoma with ALK Mutation: A Case Report
od: Ahmed Badran, i wsp.
Wydane: (2023-08-01)

Treatment of Patients with ALK Gene Rearranged Non-small Cell Lung Cancer  after Resistance to Crizotinib
od: Tao JIANG, i wsp.
Wydane: (2015-02-01)

ROS1 rearrangement and response to crizotinib in Stage IV non-small cell lung cancer
od: Moushumi Suryavanshi, i wsp.
Wydane: (2017-01-01)

Efficacy of different sequential patterns after crizotinib progression in advanced anaplastic lymphoma kinase‐positive non–small cell lung cancer
od: Xiya Ma, i wsp.
Wydane: (2022-06-01)

Crizotinib in treatment of lung cancer
od: Arpita Singh, i wsp.
Wydane: (2017-01-01)

Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report
od: Dennis Christoph Harrer, i wsp.
Wydane: (2020-10-01)

Disease Flare after Discontinuation of Crizotinib in Anaplastic Lymphoma Kinase-Positive Lung Cancer
od: Yuka Kuriyama, i wsp.
Wydane: (2013-08-01)

Hexokinases II‐mediated glycolysis governs susceptibility to crizotinib in ALK‐positive non‐small cell lung cancer
od: Caiyu Lin, i wsp.
Wydane: (2021-12-01)

Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center
od: Chang Liu, i wsp.
Wydane: (2019-10-01)

Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer
od: Chan-Young Ock, i wsp.
Wydane: (2019-09-01)

The Dual Role of Autophagy in Crizotinib-Treated ALK<sup>+</sup> ALCL: From the Lymphoma Cells Drug Resistance to Their Demise
od: Estelle Espinos, i wsp.
Wydane: (2021-09-01)

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
od: Muhammad Wasi Alam, i wsp.
Wydane: (2019-07-01)

Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China
od: Zihua Zou, i wsp.
Wydane: (2022-01-01)

Whole-process Management of Treatment of Advanced ALK Positive Non-small Cell Lung Cancer: A Case Report
od: Henan BAI, i wsp.
Wydane: (2021-08-01)

Crizotinib for recurring non‐small‐cell lung cancer with EML4‐ALK fusion genes previously treated with alectinib: A phase II trial
od: Daijiro Harada, i wsp.
Wydane: (2021-03-01)

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials
od: Scott N. Gettinger, MD, i wsp.
Wydane: (2022-09-01)

Real‐world outcome of crizotinib for anaplastic lymphoma kinase‐positive lung cancer: Multicenter retrospective analysis in South Korea
od: Da Som Jeon, i wsp.
Wydane: (2024-02-01)

Alectinib-Induced Alopecia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
od: Tomonobu Koizumi, i wsp.
Wydane: (2016-04-01)

Crizotinib-Associated Renal Cysts: A Case Series
od: Garima Suman, i wsp.
Wydane: (2019-07-01)

Efficacy of crizotinib retreatment after crizotinib-related interstitial lung disease in a patient with ROS1-rearranged advanced lung adenocarcinoma: A case report and potential crizotinib retreatment strategy
od: Woo Kyung Ryu, i wsp.
Wydane: (2022-10-01)

A Case of Orbital Metastasis as Disease Progression of Anaplastic Lymphoma Kinase-Positive Lung Cancer Treated with Crizotinib
od: Yoshihiko Sakata, i wsp.
Wydane: (2015-01-01)

Efficacy and safety of crizotinib in patients with anaplastic lymphoma kinase-positive advanced-stage non-small-cell lung cancer
od: Mohieldin A, i wsp.
Wydane: (2018-11-01)

Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib
od: Di Marino P, i wsp.
Wydane: (2020-03-01)

Molecular epidemiological study of microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene using immunohistochemistry as a cost effective alternative to fluorescence in situ hybridization for Indian patients with adenocarcinoma lung
od: Anurag Mehta, i wsp.
Wydane: (2017-01-01)

Clinical characteristics and risk factors of drug‐induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis
od: Ken Koshikawa, i wsp.
Wydane: (2020-06-01)

Successful Management of Crizotinib-Induced Neutropenia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report
od: Jun Osugi, i wsp.
Wydane: (2016-01-01)

Clinical Efficacy of Crizotinib in Advanced ALK Positive  Non-small Cell Lung Cancer
od: Jing ZHAO, i wsp.
Wydane: (2015-10-01)

Modern treatment of ALK-positive non-small cell lung cancer
od: D. A. Kharagezov, i wsp.
Wydane: (2022-06-01)

Identification of a novel ALK variant intrinsically resistant to crizotinib
od: Ullas Batra, i wsp.
Wydane: (2020-12-01)

Efficacy and Safety of Crizotinib in Advanced or Recurrent  ALK-positive Non-small Cell Lung Cancer
od: Xiaoyan LI, i wsp.
Wydane: (2019-08-01)

Development of crizotinib-associated renal cyst in a non-small cell lung cancer patient with ALK fusion: a case report and review of the literature
od: Peng Zhang, i wsp.
Wydane: (2024-04-01)

Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL
od: Wanying Liu, i wsp.
Wydane: (2024-02-01)

Alectinib versus crizotinib in ALK‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence
od: Yurong Wang, i wsp.
Wydane: (2022-12-01)

Long‐term response to crizotinib in a 17‐year‐old boy with treatment‐naïve ALK‐positive non‐small‐cell lung cancer
od: Giacomina Megaro, i wsp.
Wydane: (2022-03-01)

Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study
od: Caicun Zhou, MD, PhD, i wsp.
Wydane: (2024-09-01)

Case report: ALK-positive histiocytosis presented as bilateral synchronous breast masses with long-term remission on crizotinib
od: Yuhang Zhou, i wsp.
Wydane: (2023-11-01)

Efficacy of crizotinib therapy for a patient with non-small cell lung cancer with ALK gene rearrangement – case report and review of current therapeutic options
od: Julia Barbara Bargieł, i wsp.
Wydane: (2021-09-01)

A Case of Lung Adenocarcinoma Harboring a Rare LOC285000-ALK-NCK2 Gene Fusion Identified by Next-Generation Sequencing With Long-Term Response to Crizotinib
od: Min Zhang, MBBS, i wsp.
Wydane: (2021-02-01)